investigate effect and toxic or side-effect of Xuezhikang, ZOCOR
(Simvastatin) and Gangdejian. Method: 158 patients were divided
into three groups treated by the above three medicines respectively.
Then liver function, levels of serum TC, TG, LDL-C, HDL-C and liver
morphological change tested by B-ultrasound are observed in patients
before and after the treatment. Results: After 6 months treatment,
total efficacy of Xuezhikang reached 90.77%, total efficacy of Simvastatin
reached 66.67% and that of Gandejian 52.08%. Conclusion: Xuezhikang
had the capacity in lowering blood lipid level and inhibiting the
formation of fatty liver. And its effect was superior to Simvastatin
and Gandejian, whereas the latter two nearly performed the same.
Therefore, Xuezhikang could be used as a new medicine for fatty
[Key word]: Xuezhikang, fatty liver
criteria for fatty liver:
Clinically weakness, fatness and hepatomegaly.
elevation of ALA, the increase of serum TC, TG, LDL-C and decrease
and CT shows: hepatomegaly, degradation or decline of later liver-wave.
B-ultrasound or CT shows were quite sensitive to fatty liver.
And the diagnosis of fatty liver occurred when patients meeting
the above third standard, with or without the first and/or second
standard. All 158 patients in this study met diagnosis criteria
with 92 male and 66 female, age from 18 to 65 years old and the
average of 32.5 ▒ 18.8. 65 cases received Xuezhikang treatment,
45 cases got Simvastatin treatment and 48 cases obtained Gandejian
treatment. Every case in the three group was comparable in terms
of gender, age, state of illness and course of disease (P >
Patients in Xuezhikang group took 0.6g each time and twice a day.
Xuezhikang was manufactured by WBL Peking University Biotech Limited
Company. Patients in Simvastatin group took 10 mg such agent every
evening. Simvastatin is the product of Moshadone China Co. Ltd.
Whereas Patients in Gandejian group took Gandejian two tablets a
time twice a day. Gandejian is a product of Ronald PlankżLoann
Company of Germany. Every patient in the above groups was provided
with routine liver care within 6 months treatment. Post-treatment
investigations or follow-up visits were carried out for 3 ~ 6 months.
Venous blood samples were taken in the morning on fasting patients
before the treatment, and 8 weeks, 16 weeks and 24 weeks after the
treatment in order to test concentrations of serum TC, TG (using
enzyme method, reagent from German BecMan Co.) HDL-C and LDL-C (immune
covering method, reagent from Japan No.1 Chemical Company) and determine
ALT, AST, GLB and SB (using Monarch plus automatic biochemical analyzer).
Effects of Xuezhikang can refer to Clinical Curative Effect Standards
of Lipid Regulating Medicine stipulated by the Ministry of Health
P.R. China in 1988. In addition, criteria for other effects are as
the following: 1) Highly effective: ALT normal; B-ultrasound shows:
ordinary morphology of liver. 2) Effective: ALT normal; B-ultrasound
shows: improvements occur in hepatomegaly and rear field liver-wave
decline. 3) Ineffective: not meeting one of the above criteria.
on Weak, Overweight and Hepatomegaly Patients
After 24-week treatment, 59 cases (90.77%)
in Xuezhikang group, 15 cases (33.33%) in Simvastatin group, and
21 in Gandejian group (43.75%) had recovered from the symptoms of
weakness, overweight and hepatauxe. Inter-group data possessed significant
differences in terms of statistics (P < 0.05). This showed a
good performance of Xuezhikang in reducing body weight, eliminating
weakness and improving hepatauxe
After 24-week treatment, 62 cases (95.38%) in Xuezhikang group,
40 cases (88.89%) in Simvastatin group, and 43 cases in Gandejian
group (89.58%) obtained normal ALT. Inter-group data had no significant
differences in statistical analysis. This means that common liver
treatment plays a certain role in curing fatty liver ALT but has
little influence on lipid regulating agent.
on Blood Lipid
After 24-week treatment, some effects occurred
in reducing serum TC, TG and elevating HDL-C level. Xuezhikang and
Simvastatin performed better than Gandejian in declining serum TC
and TG. However, total efficacy of Xuezhikang and Gandejian appeared
lower than Simvastatin in elevating HDL-C level. ( Table I).
I. Comparison of lipid-lowering effect by three kinds of treatment
Effects on TC reduction: total sample comparison c2 = 19.28, P <
0.001. Xuezhikang compared with Simvastatin c2 = 1.98, P > 0.05.
The comparison between Xuezhikang and Gandejian group, c2 = 12.66,
P < 0.01. Whereas c2 = 6.79, and P < 0.05 happened between Simvastatin
and Gandejian group.
on TG reduction: total sample comparison c2 = 33.64, P < 0.001.
Xuezhikang group compared with Simvastatin group c2 = 1.32, P >
0.05. The comparison between Xuezhikang and Gandejian group, c2
= 6.89, P < 0.05. Whereas c2 = 6.79, and P < 0.05 appeared
between Simvastatin and Gandejian group.
on HDL elevation: total sample comparison c2 = 5.69, P > 0.05.
Xuezhikang group compares with Simvastatin group c2 = 10.56, P <
0.01. The comparison between Xuezhikang and Gandejian group, c2
= 1.13, P > 0.05. Whereas c2 = 25.11, and P < 0.001 occurred
between Simvastatin and Gandejian group. re
Impact on B-ultrasound Morphology
II. Comparison of B-ultrasound abnormal morphology among three
Total Efficacy (%)
three group comparison, X2 = 58.14, P < 0.001.
Xuezhikang group compared with Simvastatin group, c2 = 37.73, P
Xuezhikang group compared with Gandejian group, c2 = 39.55, P <
Simvastatin group compared with Gandejian group, c2 = 1.86, P >
Patients treated with Xuezhikang perform better in the recovery
of B-ultrasound hepatauxe and latter half liver-wave decline compared
with other two medicines.
on Fatty Liver
After 6 months treatment, 59 cases (90.77%)
obtained curative effect, with 53 cases (81.54%) were highly effective,
6 (9.23%) effective and 6 (9.23%) ineffective in fatty liver cure
in Xuezhikang group. In Simvastatin group, 30 cases (66.67%) obtained
curative effect with 10 patients (22.22%) being highly effective,
20 (44.45%) effective and 15 (33.33%) ineffective. Meanwhile, all
together 25 patients got effect in Gandejian group with 10 cases
(20.83%) acquiring distinct effect, 15 cases (31.25%) effective
and 23 cases (47.92%) ineffective. Statistic analysis indicated
P < 0.001 for data between Xuezhikang group and other two groups
illustrating a better effect of Xuezhikang than that of Simvastatin
and Gandejian. Whereas there were no significant difference between
Simvastatin and Gandejian groups (P > 0.05). Simvastatin and
Gandejian had similar effect but slightly poorer than Xuezhikang.
During Xuezhikang treatment, only one case
had single ALT 92 mmol/L. Re-examination showed a regular ALT level
after 1 month administration of smaller doage. There were also three
cases of slight stomach trouble. In Simvastatin group, 3 cases had
slight elevation of ALT. But no toxic and side-effects occurred
in Gandejian group.
and Simvastatin perform better than Gandejian in regulating lipid.
As for the improvement of B-ultrasound fatty liver morphology, Xuezhikang
was obviously superior to both Simvastatin and Gandejian. In the
treatment of fatty liver, all three medicines acquired some curative
effects. But Xuezhikang had much higher efficacy rate than that
of Simvastatin and Gandejian. Moreover, the ineffective cases in
Xuezhikang group were mainly climacteric women. It is assumed that
fatty liver of those women may have something to do with dysfunctions
of estrogenic hormone secretion. Thus, the author thinks that curative
effect could be improved during Xuezhikang treatment if some estrogenic
hormone medicines are employed at the same time.
is manufactured and refined from Chinese traditional medicine Hongqu
(red yeast rice or Monascus purpureus). It has a strong capacity
in regulating lipid metabolism and inhibiting the formation of fatty
liver resulting from high cholesterol diet. The main ingredient
HMG-CoA reductase inhibitor competitively suppresses the speed control
enzyme for cholesterol synthesis, thus cutting down the synthesis
of liver cholesterol. Meanwhile, HMG-CoA reductase inhibitor stimulates
the activity of LDL-C receptor on liver cell surface and facilitates
the elimination of serum LDL-C, affects metabolism of cholesterol
and TG in human body therefore reduces the concentration of serum
TC, TG and LDL-C and fat deposition in liver. Under normal conditions,
liver continuously moves fat outward in the form of lipoprotein,
and lipoid is the necessary material to synthesize lipoprotein.
Thus, the decrease of lipoid affects the formation and output of
lipoprotein. Xuezhikang contains various essential amino acids and
unsaturated fat acids that nourish liver cells, enhances the cell
ability to clear lipid and regulate internal metabolism of lipids.
Therefore, Xuezhikang can be used as an effective medicine for curing
fatty liver patients.